Lakamp Amanda S, Ouellette Michel M
Eppley Institute for Research in Cancer, University of Nebraska Medical Center, 985950 Nebraska Medical Center, Omaha, NE 68198-5950, USA.
J Nucleic Acids. 2011;2011:720798. doi: 10.4061/2011/720798. Epub 2011 Oct 16.
Using SELEX (systematic evolution of ligands by exponential enrichment), we serendipitously discovered a ssDNA aptamer that binds selectively to the anti-FLAG M2 antibody. The aptamer consisted of two motifs (CCTTA and TGTCTWCC) separated by 2-3 bases, and the elimination of one or the other motif abrogated binding. The DNA aptamer and FLAG peptide competed for binding to the antigen-binding pocket of the M2 antibody. In addition, the aptamer eluted FLAG-tagged proteins from the antibody, suggesting a commercial application in protein purification. These findings demonstrate the feasibility of using SELEX to develop ssDNA aptamers that block the function of a specific antibody, a capability that could lead to the development of novel therapeutic modalities for patients with systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases.
利用指数富集配体系统进化技术(SELEX),我们意外发现了一种能选择性结合抗FLAG M2抗体的单链DNA适配体。该适配体由两个基序(CCTTA和TGTCTWCC)组成,中间间隔2 - 3个碱基,去除其中任何一个基序都会消除结合。DNA适配体和FLAG肽竞争结合M2抗体的抗原结合口袋。此外,该适配体可从抗体上洗脱FLAG标签蛋白,表明其在蛋白质纯化方面具有商业应用价值。这些发现证明了利用SELEX开发能阻断特定抗体功能的单链DNA适配体的可行性,这一能力可能会为系统性红斑狼疮、类风湿关节炎和其他自身免疫性疾病患者带来新型治疗方法的发展。